Q3 2023 Holdings
Filed 2023-11-14 | 46 holdings | $6.4B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Horizon Therapeutics PLC | Common | G46188101 | $809.8M | 7,000,000 | 12.6% |
| United Therapeutics Corp(UTHR) | Common | 91307C102 | $644.3M | 2,852,500 | 10.0% |
| Argenx SE(ARGX) | Sponsored ADR | 04016X101 | $491.6M | 1,000,000 | 7.7% |
| Sarepta Therapeutics Inc(SRPT) | Common | 803607100 | $487.9M | 4,025,000 | 7.6% |
| Apellis Pharmaceuticals Inc(APLS) | Common | 03753U106 | $422.7M | 11,111,111 | 6.6% |
| Seagen Inc(SGENUSD) | Common | 81181C104 | $373.3M | 1,759,606 | 5.8% |
| Ascendis Pharma(ASND) | Sponsored ADR | 04351P101 | $343.7M | 3,670,000 | 5.4% |
| Biomarin Pharmaceutical Inc(BMRN) | Common | 09061G101 | $340.6M | 3,850,000 | 5.3% |
| Amicus Therapeutics Inc(FOLD) | Common | 03152W109 | $333.2M | 27,400,000 | 5.2% |
| Krystal Biotech Inc(KRYS) | Common | 501147102 | $297.6M | 2,565,555 | 4.6% |
| Mirati Therapeutics Inc(MRTXEUR) | Common | 60468T105 | $290.4M | 6,666,666 | 4.5% |
| Madrigal Pharmaceuticals Inc(MDGL) | Common | 558868105 | $227.1M | 1,555,000 | 3.5% |
| Alnylam Pharmaceuticals Inc(ALNY) | Common | 02043Q107 | $179.1M | 1,011,111 | 2.8% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $167.4M | 4,900,000 | 2.6% |
| Cymabay Therapeutics Inc(CBAYUSD) | Common | 23257D103 | $153.6M | 10,300,000 | 2.4% |
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $114.0M | 1,999,999 | 1.8% |
| Biocryst Pharmaceuticals Inc(BCRX) | Common | 09058V103 | $81.8M | 11,550,000 | 1.3% |
| Roivant Sciences LTD(ROIV) | Common | G76279101 | $54.3M | 4,651,162 | 0.8% |
| Kymera Therapeutics Inc(KYMR) | Common | 501575104 | $53.6M | 3,855,000 | 0.8% |
| Ultragenyx Pharmaceutical Inc(RARE) | Common | 90400D108 | $53.5M | 1,500,000 | 0.8% |
| Structure Therapeutics Inc(GPCR) | Sponsored ADR | 86366E106 | $50.4M | 1,000,000 | 0.8% |
| Nuvalent Inc(NUVL) | Common | 670703107 | $37.4M | 812,500 | 0.6% |
| Mannkind Corp(MNKD) | Common | 56400P706 | $37.2M | 9,000,000 | 0.6% |
| Syndax Pharmaceuticals Inc(SNDX) | Common | 87164F105 | $37.1M | 2,555,555 | 0.6% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $30.5M | 6,700,000 | 0.5% |
| Akero Therapeutics ORD(AKRO) | Common | 00973Y108 | $28.1M | 555,555 | 0.4% |
| Kura Oncology Inc(KURA) | Common | 50127T109 | $27.2M | 2,980,000 | 0.4% |
| Rocket Pharmaceuticals Inc(RCKT) | Common | 77313F106 | $25.6M | 1,250,000 | 0.4% |
| Marinus Pharmaceuticals Inc(MRNS*) | Common | 56854Q200 | $25.4M | 3,150,000 | 0.4% |
| Tango Therapeutics Inc(TNGX) | Common | 87583X109 | $25.0M | 2,222,222 | 0.4% |
| Monte Rosa Therapeutics Inc(GLUE) | Common | 61225M102 | $21.7M | 4,535,000 | 0.3% |
| Cerevel Therapeutics Hldng(CERE1EUR) | Common | 15678U128 | $20.9M | 955,555 | 0.3% |
| PMV Pharmaceuticals Inc(PMVP) | Common | 69353Y103 | $18.4M | 3,000,000 | 0.3% |
| Avidity Biosciences Inc(RNA) | Common | 05370A108 | $16.0M | 2,510,000 | 0.2% |
| Arrowhead Pharmaceuticals Inc(ARWR) | Common | 04280A100 | $15.2M | 565,000 | 0.2% |
| Aadi Biosciences Inc(WHWK) | Common | 00032Q104 | $13.8M | 2,849,402 | 0.2% |
| Taysha Gene Therapies Inc(TSHA) | Common | 877619106 | $12.4M | 3,925,000 | 0.2% |
| Verrica Pharmaceuticals Inc | Common | 92511W108 | $11.5M | 2,954,064 | 0.2% |
| Merus N V | Common | N5749R100 | $10.5M | 444,444 | 0.2% |
| Fennec Pharmaceuticals Inc(FENC) | Common | 31447P100 | $9.0M | 1,200,000 | 0.1% |
| Ikena Oncology Inc | Common | 45175G108 | $7.1M | 1,640,000 | 0.1% |
| Seres Therapeutics Inc(MCRB1EUR) | Common | 81750R102 | $6.0M | 2,500,000 | 0.1% |
| IO Biotech Inc(IOBT) | Common | 449778109 | $2.8M | 2,055,883 | 0.0% |
| Talaris Therapeutics Inc | Common | 87410C104 | $1.4M | 500,000 | 0.0% |
| Invesco QQQ Trust(QQQ)Put | ETF | 46090E103 | $1.2M | 500,000 | 0.0% |
| Aeglea Biotherapeutics Inc(SYRE) | Common | 00773J202 | $140.4K | 11,458 | 0.0% |